Patents by Inventor Jorge Genovese
Jorge Genovese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240108886Abstract: Described is a low voltage, pulsed electrical stimulation device for modulating the expression of sirtuin (“SIRT”), a useful protein, by tissues. Also described are methods of enhancing expression of SIRT in cells, particularly a method of stimulating the expression and/or release of SIRT in a cell having a gene encoding SIRT, wherein the method includes applying a bioelectric signal of, within 15%, 50 ?A to about 500 ?A, 20 pps, at 400 ?sec pulse duration to the cell (e.g., directly, indirectly, or wirelessly). In order to downregulate expression of SIRT, the at least one bioelectric signal has a current of at least about 1 mA, as measured at the level of the living cells.Type: ApplicationFiled: September 25, 2023Publication date: April 4, 2024Inventors: Howard J. Leonhardt, Jorge Genovese
-
Patent number: 11819688Abstract: A skin regeneration therapy combining precise bioelectric signals, light, and biologics for skin treatment and regeneration. Precise bioelectric signals give clear instructions to the stimulated cell DNA/RNA to produce specific regenerative proteins on demand. Bioelectric signals give clear instructions to cell membranes on what to let in and what to let out and serve as an equivalent or surrogate of environmental stimuli to cause a cell action in response.Type: GrantFiled: July 6, 2021Date of Patent: November 21, 2023Assignee: Leonhardt Ventures LLCInventors: Howard J. Leonhardt, Jorge Genovese
-
Publication number: 20230347144Abstract: Age is an important predictor of neuromuscular recovery after peripheral nerve injury. Insulin-like growth factor 1 (IGF-1) is a potent neurotrophic factor that is known to decline with increasing age. The purpose of this study was to determine if locally delivered IGF-1 would improve nerve regeneration and neuromuscular recovery in aged animals. Young and aged rats underwent nerve transection and repair with either saline or IGF-1 continuously delivered to the site of the nerve repair. After 3 months, nerve regeneration and neuromuscular junction morphology were assessed. In both young and aged animals, IGF-1 significantly improved axon number, diameter, and density. IGF-1 also significantly increased myelination and Schwann cell activity and preserved the morphology of the postsynaptic neuromuscular junction (NMJ), These results show that aged regenerating nerve is sensitive to IGF-1 treatment.Type: ApplicationFiled: July 5, 2023Publication date: November 2, 2023Inventors: Howard J. Leonhardt, Jorge Genovese
-
Patent number: 11691007Abstract: Described is a method of treating a subject diagnosed with cancer, breast cancer, bone cancer, lung cancer, osteoporosis, multiple myeloma, and a combination of any thereof by applying a bioelectric signal or signals that upregulate the expression of Osteoprotegerin (“OPG”) and thus beneficially effect the subject's OPG/RANKL/RANK pathway.Type: GrantFiled: June 26, 2020Date of Patent: July 4, 2023Assignee: Leonhardt Ventures LLCInventors: Howard J. Leonhardt, Jorge Genovese
-
Publication number: 20230191128Abstract: Described is a low voltage, pulsed electrical stimulation device for modulating (e.g., downregulating) expression of fatty-acid-binding protein 4 (“FABP4”) protein(s) by cellular tissues. In certain embodiments, the device is further programmed or alternatively programmed to produce a bioelectric signal or signals that upregulate expression of, for example, klotho by the tissues.Type: ApplicationFiled: December 13, 2022Publication date: June 22, 2023Inventors: Howard J. Leonhardt, Jorge Genovese
-
Publication number: 20220370791Abstract: Described is a low voltage, pulsed electrical stimulation device for modulating expression of BMP9 protein(s) by cellular tissues.Type: ApplicationFiled: May 16, 2022Publication date: November 24, 2022Inventors: Howard J. Leonhardt, Jorge Genovese
-
Publication number: 20220152195Abstract: Described are methods of treating a mammalian subject who is intending to undergo exposure to an inoculant comprising a virus, polynucleotide(s) encoding at least a portion of the virus, and/or epitope(s) of the virus, the method including administering at least one bioelectric signal to the subject before exposure to the inoculant in such a manner as to increase the subject's T cell count and/or T helper cell count. Also described are methods of treating a mammalian subject undergoing a viral infection, the method comprising: administering bioelectric signals to the subject so as to upregulate expression of SDF-1 in the subject, upregulate expression of PDGF in the subject, upregulate stem cell proliferation in the subject, and upregulate expression of klotho in the subject; reducing inflammation in the subject, and administering bioelectric signals to the subject so as to stimulate regeneration of the subject's lungs and blood vessels.Type: ApplicationFiled: November 15, 2021Publication date: May 19, 2022Inventors: Howard J. Leonhardt, Jorge Genovese
-
Patent number: 11185691Abstract: Described are a system and method that “reads” cancer tumors real time and custom delivers individualized bioelectric therapy to the patient. For example, the system reads a cancer tumor, and based upon this read, delivers to the subject “a confounding signal” to jam communication within that tumor. A cancer tumor may change its communication patterns and the therapy is designed to change with these patterns, attempting to always jam the relevant communication signaling pathway. The described system includes parameters not tied to communication jamming, which should also be customized to induce apoptosis to the cancer tumor. Such parameters include signals for starving a cancer tumor of blood supply and signals for changing the cancer tumor's surface proteins and/or charge so that the immune system attacks the cancer tumor.Type: GrantFiled: September 20, 2018Date of Patent: November 30, 2021Assignee: LEONHARDT VENTURES LLCInventors: Howard J. Leonhardt, Jorge Genovese
-
Publication number: 20210339018Abstract: A skin regeneration therapy combining precise bioelectric signals, light, and biologics for skin treatment and regeneration. Precise bioelectric signals give clear instructions to the stimulated cell DNA/RNA to produce specific regenerative proteins on demand. Bioelectric signals give clear instructions to cell membranes on what to let in and what to let out and serve as an equivalent or surrogate of environmental stimuli to cause a cell action in response.Type: ApplicationFiled: July 6, 2021Publication date: November 4, 2021Inventors: Howard J. Leonhardt, Jorge Genovese
-
Publication number: 20210236817Abstract: Described is a low voltage, pulsed electrical stimulation device for controlling expression of, for example, follistatin, a muscle formation promotion protein, by tissues. Epicardial stimulation is especially useful for heart treatment. Follistatin controlled release is also useful for treating other ailments, such as erectile dysfunction, aortic aneurysm, and failing heart valves.Type: ApplicationFiled: March 29, 2021Publication date: August 5, 2021Inventors: Howard J. Leonhardt, Jorge Genovese
-
Patent number: 11052247Abstract: A skin regeneration therapy combining precise bioelectric signals, light, and biologics for skin treatment and regeneration. Precise bioelectric signals give clear instructions to the stimulated cell DNA/RNA to produce specific regenerative proteins on demand. Bioelectric signals give clear instructions to cell membranes on what to let in and what to let out and serve as an equivalent or surrogate of environmental stimuli to cause a cell action in response.Type: GrantFiled: September 12, 2018Date of Patent: July 6, 2021Assignee: LEONHARDT VENTURES LLCInventors: Howard J. Leonhardt, Jorge Genovese
-
Publication number: 20210121681Abstract: A method of using a bioelectric stimulator for delivering an electrical signal to a subject's tissue, wherein the bioelectric stimulator utilizes the electrical signal to precisely control protein expression and/or release in the tissue on demand so as to increase milk production in a subject, the method including: delivering selected electrical signals to the subject so as to precisely control protein expressions and/or release to increase milk production in the subject.Type: ApplicationFiled: April 1, 2019Publication date: April 29, 2021Inventors: Howard J. Leonhardt, Paul Norman, Jorge Genovese, Leslie Miller
-
Patent number: 10960206Abstract: Described is a low voltage, pulsed electrical stimulation device for controlling expression of, for example, follistatin, a muscle formation promotion protein, by tissues. Epicardial stimulation is especially useful for heart treatment. Follistatin controlled release is also useful for treating other ailments, such as erectile dysfunction, aortic aneurysm, and failing heart valves.Type: GrantFiled: November 14, 2017Date of Patent: March 30, 2021Assignee: LEONHARDT VENTURES LLCInventors: Howard J. Leonhardt, Jorge Genovese
-
Publication number: 20200330753Abstract: Described is a bioelectric stimulating device for reducing orthodontic treatment time (braces or aligners) with post-treatment stability enhancement. The device and associated methods provide a native sustainable optimal upregulated expression and/or release of an increase in the quantity of the right cells and proteins over time and in the right sequence to optimize tooth movement with the braces or aligners by accelerating bone resorption at the leading edge of the tooth during movement. This acceleration phenomenon is responsible for being able to shorten orthodontic treatment time. Following the final alignment of the teeth, the same device can utilize the native response and accelerate the tooth/bone interface stability by targeting specific cells and proteins that are responsible for bone deposition (hardening) in order to shorten the retention phase, while greatly decreasing the chance of relapse (instability).Type: ApplicationFiled: June 29, 2020Publication date: October 22, 2020Inventors: Howard J. Leonhardt, John Joseph Marchetto, Jorge Genovese, Alex Richardson
-
Publication number: 20200330759Abstract: Described is a method of treating a subject diagnosed with cancer, breast cancer, bone cancer, lung cancer, osteoporosis, multiple myeloma, and a combination of any thereof by applying a bioelectric signal or signals that upregulate the expression of Osteoprotegerin (“OPG”) and thus beneficially effect the subject's OPG/RANKL/RANK pathway.Type: ApplicationFiled: June 26, 2020Publication date: October 22, 2020Inventors: Howard J. Leonhardt, Jorge Genovese
-
Patent number: 10695563Abstract: Described is a bioelectric stimulating device for reducing orthodontic treatment time (braces) with post-treatment stability enhancement. The device and associated methods provide a native sustainable optimal release of an increase in the quantity of the right cells and proteins over time and in the right sequence to optimize tooth movement with the braces by accelerating bone resorption at the leading edge of the tooth during movement. This acceleration phenomenon is responsible for being able to shorten orthodontic treatment time. Following the final alignment of the teeth, the same device can utilize the native response and accelerate the tooth/bone interface stability by targeting specific cells and proteins that are responsible for bone deposition (hardening) in order to shorten the retention phase, while greatly decreasing the chance of relapse (instability).Type: GrantFiled: March 28, 2017Date of Patent: June 30, 2020Assignee: CALXSTARS BUSINESS ACCELERATOR, INC.Inventors: Howard J. Leonhardt, Jorge Genovese, John Joseph Marchetto
-
Patent number: 10646644Abstract: Described is a low voltage, pulsed electrical stimulation device for controlling expression of, for example, follistatin, a muscle formation promotion protein, by tissues. Epicardial stimulation is especially useful for heart treatment. Follistatin controlled release is also useful for treating other ailments, such as erectile dysfunction, aortic aneurysm, and failing heart valves.Type: GrantFiled: March 15, 2017Date of Patent: May 12, 2020Assignee: CalXStars Business Accelerator, Inc.Inventors: Howard J. Leonhardt, Jorge Genovese
-
Publication number: 20190030330Abstract: Described are a system and method that “reads” cancer tumors real time and custom delivers individualized bioelectric therapy to the patient. For example, the system reads a cancer tumor, and based upon this read, delivers to the subject “a confounding signal” to jam communication within that tumor. A cancer tumor may change its communication patterns and the therapy is designed to change with these patterns, attempting to always jam the relevant communication signaling pathway. The described system includes parameters not tied to communication jamming, which should also be customized to induce apoptosis to the cancer tumor. Such parameters include signals for starving a cancer tumor of blood supply and signals for changing the cancer tumor's surface proteins and/or charge so that the immune system attacks the cancer tumor.Type: ApplicationFiled: September 20, 2018Publication date: January 31, 2019Inventors: Howard J. Leonhardt, Jorge Genovese
-
Publication number: 20190015661Abstract: Described is a skin regeneration therapy. The described therapy combines precise bioelectric signals, light, and biologics for skin treatment and regeneration. Precise bioelectric signals give clear instructions to the stimulated cell DNA/RNA to produce specific regenerative proteins on demand. Bioelectric signals give clear instructions to cell membranes on what to let in and what to let out and serve as an equivalent or surrogate of environmental stimuli to cause a cell action in response.Type: ApplicationFiled: September 12, 2018Publication date: January 17, 2019Inventors: Howard J. Leonhardt, Jorge Genovese
-
Publication number: 20180064935Abstract: Described is a low voltage, pulsed electrical stimulation device for controlling expression of, for example, follistatin, a muscle formation promotion protein, by tissues. Epicardial stimulation is especially useful for heart treatment. Follistatin controlled release is also useful for treating other ailments, such as erectile dysfunction, aortic aneurysm, and failing heart valves.Type: ApplicationFiled: November 14, 2017Publication date: March 8, 2018Inventors: Howard J. Leonhardt, Jorge Genovese